Title : Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.

Pub. Date : 2008 Jan 1

PMID : 18172273






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 FOLFIRI alone did not affect pEGFR, but inhibited epidermal proliferation and activated mitogen-activated protein kinase (MAPK) and induced p27 expression in the skin. FOLFIRI regimen interferon alpha inducible protein 27 Homo sapiens